Braveheart Bio (BRVE) vs Nuvation Bio (NUVB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nuvation Bio is the larger company by market cap ($1.74 billion vs $1.72 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRVE | NUVB |
|---|---|---|
| Share price | $19.09 | $4.95 |
| Market cap | $1.72B | $1.74B |
| 1-day change | +2.74% | +1.85% |
| YTD return | — | -44.75% |
| 1-year return | — | +33.06% |
| 5-year return | — | -48.17% |
| EPS (TTM) | $-6.08 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $32.00 | $9.75 |
| 52-week low | $17.86 | $3.36 |
| Distance from 52-week high | -40.34% | -49.23% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +137.04% | +162.63% |
| Average volume | 558.38K | 5.65M |
| Shares outstanding | 90.04M | 350.12M |
| Employees | 49 | 305 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Braveheart Bio
BRVE stock →Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Nuvation Bio
NUVB stock →Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 305 employees
BRVE vs NUVB FAQ
Which is bigger, Braveheart Bio or Nuvation Bio?
Nuvation Bio (NUVB) is larger, with a market capitalization of $1.74B compared with $1.72B for Braveheart Bio (BRVE).
Are Braveheart Bio and Nuvation Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.